BiomeBank Announces Regulatory Approval for Donor Derived Microbiome Drug

Whitley Workstation customer, BiomeBank, receives TGA (Therapeutic Goods Administration) approval for a donor derived microbiome drug. The drug - BIOMICTRA - will be used for restoration of gut microbiota in the treatment of recurrent Clostridioides difficile infection. A recent article in the publication Microbiome Times tell the story:

https://www.microbiometimes.com/biomebank-announces-regulatory-approval-for-donor-derived-microbiome-drug/

BiomeBank, based in Adelaide, Australia, are the proud owners of a Whitley A85 HEPA Workstation, which will be joined by an A55 Workstation early in 2023.